AIM: TT virus (TTV) is a newly described DNA virus related to postransfusion hepatitis that produces persistent viremia in the absence of clinical manifestations. PEG-IFN plus ribavirin have been useful in the treatment of chronic hepatitis C infection. This study investigated the responses of TT virus (TTV) and hepatitis C virus (HCV) to PEG-IFN plus ribavirin therapy. METHODS:Fifteen patients infected with HCV were treated with PEG-IFN(0.5 microg/body weight/week) and ribavirin (1 000 mg-1 200 mg/daily) for 48 weeks. Blood samples were drawn at the beginning and the end of the therapy. Serum TTV DNA and HCV RNA were quantified by real time PCR. RESULTS: At the beginning of treatment, TTV infection was detected in 10/15 (66.6%) of HCV-infected patients. Loss of serum TTV DNA at the end of therapy occurred in 6/10 (60%) patients. Out of these 6 patients, 4 (67%) became positive for TTV DNA after 6 months of therapy. Regarding HCV viremia, 11/15 (73%) patients were negative for serum HCV RNA after 48 weeks of therapy, 7/11 (64%) of these cases also became negative for TTV DNA following the combined treatment. In the 3/4 (75%) patients who were positive for HCV RNA at the end of therapy, TTV DNA was detected as well. Sustained HCV response at 6 months after treatment was 53% (8/15). CONCLUSION: No TTV sustained response can be achieved in any patient after PEG-IFN plus ribavirin administration.
RCT Entities:
AIM: TT virus (TTV) is a newly described DNA virus related to postransfusion hepatitis that produces persistent viremia in the absence of clinical manifestations. PEG-IFN plus ribavirin have been useful in the treatment of chronic hepatitis C infection. This study investigated the responses of TT virus (TTV) and hepatitis C virus (HCV) to PEG-IFN plus ribavirin therapy. METHODS: Fifteen patients infected with HCV were treated with PEG-IFN(0.5 microg/body weight/week) and ribavirin (1 000 mg-1 200 mg/daily) for 48 weeks. Blood samples were drawn at the beginning and the end of the therapy. Serum TTV DNA and HCV RNA were quantified by real time PCR. RESULTS: At the beginning of treatment, TTV infection was detected in 10/15 (66.6%) of HCV-infectedpatients. Loss of serum TTV DNA at the end of therapy occurred in 6/10 (60%) patients. Out of these 6 patients, 4 (67%) became positive for TTV DNA after 6 months of therapy. Regarding HCV viremia, 11/15 (73%) patients were negative for serum HCV RNA after 48 weeks of therapy, 7/11 (64%) of these cases also became negative for TTV DNA following the combined treatment. In the 3/4 (75%) patients who were positive for HCV RNA at the end of therapy, TTV DNA was detected as well. Sustained HCV response at 6 months after treatment was 53% (8/15). CONCLUSION: No TTV sustained response can be achieved in any patient after PEG-IFN plus ribavirin administration.
Authors: S Brillanti; J Garson; M Foli; K Whitby; R Deaville; C Masci; M Miglioli; L Barbara Journal: Gastroenterology Date: 1994-09 Impact factor: 22.682
Authors: X W Meng; M Komatsu; T Goto; K Nakane; S Ohshima; K Yoneyama; J G Lin; S Watanabe Journal: J Gastroenterol Hepatol Date: 2001-02 Impact factor: 4.029
Authors: W L Irving; J K Ball; S Berridge; R Curran; A M Grabowska; C L Jameson; K R Neal; S D Ryder; B J Thomson Journal: J Infect Dis Date: 1999-07 Impact factor: 5.226
Authors: Y Nishizawa; E Tanaka; K Orii; A Rokuhara; T Ichijo; K Yoshizawa; K Kiyosawa Journal: J Gastroenterol Hepatol Date: 2000-11 Impact factor: 4.029